FDA’s Updated Biosimilar Policy: What it really means in the US, EU5, Japan, and China
The regulatory landscape for biosimilars is shifting significantly in 2025. The FDA has taken two big steps that collectively make it faster and cheaper to bring many biosimilars to market:In June 202 ...
Pharma GCC Setup: A Strategic Feasibility Framework for Location and Talent Decisions
The pharma industry has seen a wave of change over the decades, driven by digital innovation, data analytics & global collaboration. A major catalyst behind this change has been the rise of Global ...